Drugs in liver disease

被引：18

作者：

Branch, RA ^{[1
]}

机构：

[1] Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 1998年 / 64卷 / 04期

关键词：

D O I：

10.1016/S0009-9236(98)90077-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：462 / 465

页数：4

共 13 条

[1] Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6 [J].

Adedoyin, A ;

Arns, PA ;

Richards, WO ;

Wilkinson, GR ;

Branch, RA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :8-17

[2]

ADEDOYIN A, 1996, HEPATOLOGY TXB LIVER, V1, P307

[3] Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis [J].

Arns, PA ;

Adedoyin, A ;

DiBisceglie, AM ;

Waggoner, JG ;

Hoofnagle, JH ;

Wilkinson, GR ;

Branch, RA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :527-537

[4] THE METABOLISM AND BIOAVAILABILITY OF MORPHINE IN PATIENTS WITH SEVERE LIVER-CIRRHOSIS [J].

HASSELSTROM, J ;

ERIKSSON, S ;

PERSSON, A ;

RANE, A ;

SVENSSON, JO ;

SAWE, J .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (03) :289-297

[5]

KRAUS JW, 1978, CLIN PHARMACOL THER, V24, P411

[6]

KUBISTY CA, 1995, POCKET BOOK CRITICAL, P91

[7] THE DISPOSITION OF DAPSONE IN CIRRHOSIS [J].

MAY, DG ;

ARNS, PA ;

RICHARDS, WO ;

PORTER, J ;

RYDER, D ;

FLEMING, CM ;

WILKINSON, GR ;

BRANCH, RA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (06) :689-700

[8]

PATWARDHAN RV, 1981, GASTROENTEROLOGY, V81, P1006

[9]

SHAND DG, 1978, LIVER QUANTITATIVE A, P346

[10] GLUCURONIDATION OF OXAZEPAM IS NOT SPARED IN PATIENTS WITH HEPATIC-ENCEPHALOPATHY [J].

SONNE, J ;

ANDREASEN, PB ;

LOFT, S ;

DOSSING, M ;

ANDREASEN, F .

HEPATOLOGY, 1990, 11 (06) :951-956

← 1 2 →